UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 120.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,449,277 shares of the company's stock after buying an additional 1,337,257 shares during the quarter. Point72 Asset Management L.P. owned 10.44% of UroGen Pharma worth $41,099,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Cubist Systematic Strategies LLC grew its stake in shares of UroGen Pharma by 630.9% in the second quarter. Cubist Systematic Strategies LLC now owns 44,949 shares of the company's stock valued at $754,000 after buying an additional 38,799 shares in the last quarter. Great Point Partners LLC increased its stake in UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company's stock worth $48,767,000 after purchasing an additional 285,714 shares during the period. Marshall Wace LLP acquired a new stake in shares of UroGen Pharma during the second quarter worth about $719,000. ProShare Advisors LLC purchased a new position in shares of UroGen Pharma in the second quarter valued at approximately $199,000. Finally, Main Street Financial Solutions LLC acquired a new position in shares of UroGen Pharma in the second quarter valued at approximately $403,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

URGN has been the subject of several recent research reports. Oppenheimer raised their price target on shares of UroGen Pharma from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, June 14th. LADENBURG THALM/SH SH upped their price target on UroGen Pharma from $48.00 to $53.50 and gave the stock a "buy" rating in a report on Friday, June 14th. Guggenheim started coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of UroGen Pharma in a research note on Wednesday, August 14th.

UroGen Pharma Stock Down 0.9 %

Shares of URGN traded down $0.11 during mid-day trading on Thursday, reaching $12.75. The company's stock had a trading volume of 399,738 shares, compared to its average volume of 477,328. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93. UroGen Pharma Ltd. has a 12-month low of $10.60 and a 12-month high of $20.70. The stock has a market cap of $299.04 million, a PE ratio of -3.75 and a beta of 1.11. The company's 50 day moving average is $14.56 and its 200 day moving average is $14.68.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.49 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.